NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments
Binding term sheet to divest legacy Mazindol CVR assets to REA for $30K cash, 9.4% equity stake and up to $55M milestones plus royalties.
What this release says
NewcelX has signed a binding term sheet to sell its worldwide Mazindol asset portfolio, the legacy CVR assets, to REA Holdings. The deal is subject to definitive documentation and customary closing conditions, so it has not closed yet. For a shareholder, it removes a legacy asset from NewcelX's books while keeping some upside through equity, milestones and royalties, and the remaining value is shared with CVR holders under the CVR agreement.
Key figures
- Upfront consideration
- $500,000
- Cash portion of upfront
- $30,000
- Equity stake in REA Holdings
- 9.4% of fully diluted equity
- Potential milestone payments
- up to $55 million
- Royalty range on net sales
- 2% to 8%
Positive for shareholders
- NewcelX receives upfront cash and equity without funding Mazindol development itself.
- NewcelX may receive milestone payments and royalties if Mazindol products advance and sell.
- The divestiture lets NewcelX focus on its core cell-therapy pipeline led by NCEL-101.
Negative for shareholders
- Most of the upfront value is paid in shares rather than cash.
- Payments to CVR holders are net of costs NewcelX is entitled to deduct.
- The milestone and royalty payments are contingent and depend on future development and sales.
Written by Quantisnow AI from this release. Not financial advice.
Key terms
- Contingent value rights (CVR):
- A right given to shareholders that pays them extra amounts if certain future events, such as asset sales or milestones, occur.
- Binding term sheet:
- A preliminary agreement setting out key deal terms that both sides are legally bound to, before the full contract is signed.
- Fully diluted equity:
- The total share count assuming all options, warrants and convertible securities have been exercised, so each holder's stake is measured on that basis.
- Milestone payments:
- Payments made when specified development, regulatory or sales goals are reached.
FAQ
What is NewcelX selling to REA Holdings?
NewcelX is selling its worldwide Mazindol asset portfolio, referred to as the CVR assets, including intellectual property, clinical and regulatory data, formulations and manufacturing documentation.
How much is NewcelX getting upfront?
The binding term sheet provides $500,000 in attributed upfront consideration, of which $30,000 is cash and the rest is shares representing 9.4% of REA's fully diluted equity after closing.
Is the transaction complete?
Not yet. The transaction remains subject to entry into definitive documentation, customary closing conditions and applicable corporate and CVR requirements.
Historical context for NCEL
Across the 12 sessions after earlier NCEL headlines, the stock closed higher 7 times and lower 5 times, with a median move of 4.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NCEL | SPY |
|---|---|---|---|
| Sep 28, 2026 | NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes | -0.9% | -0.7% |
| Jul 31, 2026 | NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing | +3.8% | +0.7% |
| Jul 15, 2026 | NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio | -1.3% | +0.4% |
| Jul 8, 2026 | NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board | +5.5% | -0.3% |
| Jun 15, 2026 | NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform | -0.9% | +1.8% |
| Apr 1, 2026 | NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing | +10.8% | +0.8% |
Keep researching NCEL
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Follow NCEL and get a push notification the moment its next story breaks.